Reckitt Benckiser: The Suboxone Safety Pitch and the Generic Threat

In the Reckitt Benckiser Suboxone government settlement, the former parent of Suboxone’s maker agreed to pay $700 million to resolve civil allegations that its Suboxone marketing caused false claims to government health care programs. The government alleged that the company sold physicians and Medicaid agencies a safety advantage for Suboxone Film while using safety concerns about tablets to delay cheaper generic competition. The sales pitch and the effort to keep competitors out carried the same message.

The civil agreement was part of the broader $1.4 billion resolution that the Department of Justice announced on July 11, 2019. Reckitt Benckiser Group plc was the former parent of Indivior, the business previously known as Reckitt Benckiser Pharmaceuticals. That business marketed and sold Suboxone across the United States while it was Reckitt’s wholly owned subsidiary. Reckitt spun it off in December 2014.

The civil settlement concerned Reckitt’s own alleged conduct, directly or through its subsidiaries, from 2010 through 2014. The Federal Trade Commission separately reached a $50 million agreement with Reckitt over efforts allegedly designed to impede generic competition.

The Safety Claims Behind the Suboxone Civil Settlement

The Suboxone civil settlement addressed alleged promotion that reached both the prescribing decision and the government programs paying for the drug. Suboxone treats opioid addiction by helping people avoid or reduce withdrawal symptoms during treatment. The government’s allegations concerned how the company sold that treatment and the claims it made for the film version.

According to the civil allegations described by the Justice Department, Reckitt promoted Suboxone to physicians who wrote prescriptions without counseling or psychosocial support. The government alleged promotion for uses that were unsafe, ineffective and medically unnecessary, with the drug often diverted to uses without a legitimate medical purpose.

The comparative claims were specific. Reckitt allegedly told physicians and state Medicaid agencies that film was less susceptible to diversion and abuse than other buprenorphine products. It also allegedly claimed that children were less likely to be accidentally exposed to film than to tablets. The government described those claims as false and misleading.

The alleged safety message gave a physician a reason to prescribe the film and a state Medicaid agency a reason to pay for it. The same asserted advantage could serve the commercial case in both rooms. For someone who worked on the medical review, sales training or Medicaid presentation, the important question is what supported the comparison being sold.

Tablets, Film and the Threat of Generic Competition

The government’s generic-delay allegation centered on a safety petition and other steps intended to keep competing Suboxone products off the market. The government alleged that Reckitt submitted a petition to the Food and Drug Administration on September 25, 2012, claiming that it had discontinued Suboxone tablets because of safety concerns. The civil settlement addressed allegations that the petition and other actions sought to delay generic entry and improperly control prices, including prices paid by federal healthcare programs.

The commercial sequence appears more clearly in a separate state antitrust announcement from September 26, 2016. That action concerned Reckitt Benckiser Pharmaceuticals, by then known as Indivior. The states said the company introduced Suboxone tablets in 2002 with seven years of protection from generic competition. Before that protection ended, it worked with MonoSol Rx to develop a dissolvable film.

The states alleged that the operating company steered prescribers from tablets to film through marketing, price adjustments and other methods, then removed the tablets from the U.S. market after most prescriptions had shifted to film. They said purchasers had paid artificially high prices since late 2009, when generic alternatives might otherwise have become available. Annual Suboxone sales topped $1 billion during that period.

The states also alleged that the company continued selling tablets in other countries after withdrawing them in the United States. That is the uncomfortable detail in the safety explanation. A product allegedly too concerning to keep on the American market remained on sale elsewhere. The states said purchasers paid artificially high prices as a result, making addiction treatment more expensive for the government agencies buying it.

A standard generic application matches the reference drug’s active ingredient, strength, dosage form and route, as well as demonstrating bioequivalence. A competing tablet is aimed at the tablet product. Moving prescribing to film changes the product that the generic tablet must compete against. That is the commercial point of the alleged product hopping: move demand to the new version before the old one faces cheaper competition.

Are Pharmaceutical Companies Liable for False Claims?

Pharmaceutical companies are liable for knowingly causing false claims to government programs even when someone else submits the bill. The connection between promotion and government payment is what brings a manufacturer’s conduct into a False Claims Act case. In Reckitt’s civil settlement, the government alleged that the marketing caused false claims to be submitted. That link to public money also runs through other pharmaceutical fraud cases.

The agreed civil payment included $500 million for the federal government and up to $200 million for states choosing to participate. It resolved claims against Reckitt in six qui tam lawsuits brought under the False Claims Act’s whistleblower provisions.

A sales presentation shows what physicians heard. A Medicaid presentation shows what the payer heard. Our whistleblower experts work with you to connect those messages to the prescriptions and public payments behind a manufacturer’s false-claims case.

What the FTC Suboxone Settlement Changed

The FTC Suboxone settlement restricted future regulatory petitions and product withdrawals as well as resolving separate competition allegations.

If Reckitt filed a citizen petition concerning a drug, it had to disclose all relevant studies and data to both the FDA and the FTC at the same time. That requirement speaks directly to an insider who knows what a safety presentation included and what it left out.

Reckitt also agreed not to withdraw a drug or otherwise disadvantage it after obtaining approval to market another drug with the same active ingredient. The restriction reached the commercial move at the center of the allegations: replacing an older drug while restricting access to it.

What Evidence Is Needed to Prove Fraud?

Proving a case like this means connecting the safety claim to prescriptions and government payments. Our whistleblower experts work through those connections with you, including how the safety explanation fits the company’s plans for generic competition.

The civil allegations reached marketing to physicians, representations to state Medicaid agencies and a petition to the FDA. An insider’s value lies in knowing where the message changed between the underlying data and the version delivered outside the company. Knowing how a claim was approved inside the business makes the difference between a public sales pitch and an account of how it was built.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In this case, whistleblowers brought the lawsuits whose claims against Reckitt the civil settlement resolved.

For a pharmaceutical employee, the opportunity starts with what you know about the company’s conduct and its connection to government payments.

You Know How the Safety Pitch Was Built

If you saw a safety claim outrun the supporting data, or a product withdrawal planned around a generic rival, talk with our whistleblower experts about what happened inside the company. We build the pharmaceutical fraud case with you, find whistleblower lawyers who understand drug promotion and government reimbursement, and stay beside you as the case moves forward.